{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"EGFR Mutations Percentage is calculated as the percentage of patients who have activating EGFR mutations among all screened patients.","groups":[{"description":"Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"populationDescription":"The study was terminated early after the enrollment of two participants and the data were not collected.","reportingStatus":"POSTED","timeFrame":"Baseline","title":"EGFR Mutations Percentage","type":"SECONDARY"}